



LIAI Board of Directors

**Samuel Strober, M.D.
Board Chairman**

Dr. Strober has served as Professor of Medicine at Stanford University School of Medicine, Division of Immunology and Rheumatology, since 1982. He held the position of Chief of that division from 1978 to 1997, having first arrived at the School of Medicine as a Senior Assistant Resident in 1970. He has been President of the Clinical Immunology Society, and is co-founder of two biotechnology companies.

Dr. Strober's research has focused on the immune cell interactions that prevent graft versus host disease and retain graft anti-tumor activity after bone marrow transplantation, as well as cell interactions that prevent rejection of organ transplants in the absence of immunosuppressive drugs. He is also interested in the pathogenesis of systemic lupus erythematosus, a disease in which the immune system causes excessive inflammation leading to the damage of multiple organs. Throughout his career, Dr. Strober has published over 300 peer-reviewed articles in scientific journals, and has served on editorial boards of immunology journals.

Dr. Strober received his B.A. from Columbia University and his M.D. from Harvard University. He completed fellowships in the Surgical Research Laboratory at the Peter Bent Brigham Hospital in Boston, and in the Sir William Dunn School of Pathology in Oxford University followed by an internship in medicine at Massachusetts General Hospital. Prior to joining Stanford, Dr. Strober completed additional postdoctoral training as a Research Associate in the Laboratory of Cell Biology of the National Cancer Institute, Bethesda.

Katsuhiko Asano, Ph.D.

Dr. Asano is a Managing Executive Officer of Kirin Brewery Company, Ltd. in Tokyo, and President of Kirin's Pharmaceutical Division. He joined Kirin in 1970 and moved to the Pharmaceutical Division in 1985 as Manager of the Pharmaceutical Research Laboratory. One of Kirin's three primary pharmaceutical interests is in immune system diseases, focusing specifically on the development of advanced pharmaceutical products involving human antibodies and cell therapy.

Dr. Asano received his B.S. and M.S. degrees in Food Chemistry, and a Ph.D. in Biochemistry from the University of Tokyo. He has been a member of the Board of Kirin Kunpeng (China) Bio-Pharmaceutical Co., Ltd. since 1997, and also served as Chairman of the Board of Kirin-Amgen Inc. from 1996 to 2001.

Harold G. Buchanan, II

Mr. Buchanan is a Managing Member of CE2 Capital Partners LLC, an asset management firm based in San Diego that invests in environmental markets throughout the world. Prior to launching the firm, Mr. Buchanan spent 18 years in the energy industry, serving in various management and executive positions at three of the nation's largest energy firms, Sempra, Enron and Accenture.

- more -



LIAI Board of Directors – Page 2

Mr. Buchanan holds an M.B.A from the Massachusetts Institute of Technology's Sloan School of Management and a degree in Finance from the Fisher College of Business at The Ohio State University. He serves as a guest lecturer at Fisher, giving talks on topics such as finance, strategy, ethics and corporate governance and is a member of the school's Committee of Curriculum Advisors to the Chairman.

During the last several years, Mr. Buchanan has become active in the Tech Coast Angels, the largest angel investors group in California and the United States. The group, composed of successful business people, provides seed money and capital for early-stage technology and life science companies. Its members also provide mentoring and coaching to aid the entrepreneurs.

Nabil Hanna, Ph.D.

Dr. Hanna is a highly recognized scientist and retired executive from Biogen IDEC Inc. in San Diego, a pharmaceutical development company. During his 14 years there, he led the company's Research and Preclinical Development division, serving as its Chief Scientific Officer and Senior Vice President. He led a research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of B cell lymphoma.

With a career spanning more than 30 years, Dr. Hanna's research has focused on developing immunotherapies for the treatment of cancer and autoimmune diseases. He started his career as a postdoctoral fellow at the Tufts Medical School in Boston and later was a researcher at the Hebrew University Medical School in Israel and the NCI-Frederick Cancer Research Center. He joined SmithKline Beecham Pharmaceuticals in 1981 and directed various immunology research programs during his nine years there.

Dr. Hanna received his B.S. and M.S. degrees in Microbiology and his Ph.D. in Immunology from Hebrew University of Jerusalem in Israel. He co-authored more than 120 publications and is a co-inventor of 23 patents, has served as an associate editor for two scientific journals, *Cancer Research and Natural Immunity and Cell Growth Regulation*, and co-authored the book, "Host Defenses and Immunomodulation to Intracellular Pathogens." He belongs to several professional organizations, has served on various scientific advisory boards.

Mitchell Kronenberg, Ph.D.

Mitchell Kronenberg was appointed President of La Jolla Institute for Allergy and Immunology in September 2003. He is responsible for the overall administration of physical resources, finances and space at the Institute; and works with the Institute's board of directors, faculty, and executive management to develop and implement strategic plans for shaping the Institute's future.

- more -



LIAI Board of Directors – Page 3

In addition to his duties as LIAI's chief executive officer, Dr. Kronenberg serves as Scientific Director of the Institute and Head of the Division of Developmental Immunology. He conducts an active research program on the development of the immune system and the pathogenesis of autoimmune disease, and is a world-renowned expert in the field of mucosal and innate immunity.

Dr. Kronenberg graduated with a bachelor's degree in biochemistry from Columbia University, and earned his Ph.D. from the California Institute of Technology (Caltech) in 1983. He stayed on at Caltech as a postdoctoral fellow, and joined the faculty of the UCLA School of Medicine in 1986, serving first as Assistant, and later as Associate and full Professor. In 1997, he moved to LIAI to head the Division of Developmental Immunology. He also is an Adjunct Professor of Biology at the University of California, San Diego.

Dr. Kronenberg is the co-author of more than 160 scientific publications and holds five research grants from the National Institutes of Health (NIH). He has served on a number of grant review panels for NIH and other private medical research agencies, and is on the editorial board of four scientific journals. He is the winner of the Richard Dwyer award for cancer research (UCLA) and has been the Kroc Professor of Medicine at the University of California, Davis, and the Wellcome Foundation visiting Professor at Harvard University.

Susan L. Swain, Ph.D.

Dr. Swain is the Director of the Trudeau Institute, an independent immunology research center in New York. The Institute's research focuses on the body's immune system and response to infectious disease. The studies endeavor to discover how to strengthen vaccines and ongoing immune response functions to fight pandemic influenza, tuberculosis, cancer, AIDS-related infections and other life-threatening infectious diseases.

Dr. Swain holds a Ph.D. in Immunology from Harvard Medical School and a B.A. in Biology from Oberlin College in Ohio. She was a Postdoctoral Fellow at the University of California, San Diego (UCSD) in the Department of Biology and went on to become a UCSD Associate Professor of Biology and Professor of Biology.

Dr. Swain has served as an associate editor for various scientific publications, including the *Journal of Experimental Medicine* and the *Journal of Immunology* and also sat on the editorial boards of *Cellular Immunology*, *Cell* and *Lymphokines*. She was elected president of the American Association of Immunologists (AAI) in 2004 and currently serves on the AAI council. She has also served on numerous advisory boards including the Arthritis Foundation's Cellular Immunology Review Panel and the National Institutes of Health (NIH) AIDS Research Advisory Committee. Dr. Swain received the NIH Merit Award in 1996 and in 2005 and was named a New York State Woman of Distinction in 2002. She has organized several international and national meetings and has published 170 scientific papers.

- more -



LIAI Board of Directors – Page 4

**Frank J. Dixon, M.D.,
Director Emeritus**

As founder of the Research Institute of Scripps Clinic (now known as The Scripps Research Institute) in 1961, Dr. Dixon served as its director until 1987, guiding the growth of the Institute into the largest private research institute in the United States. Simultaneously, he chaired Scripps' Biomedical Research Departments from 1970 to 1974. While at Scripps, Dr. Dixon received the Albert Lasker Medical Research Award in 1975 for his outstanding contributions to the creation of a new medical discipline - immunopathology - constituting a breakthrough in medicine that illuminated the underlying mechanisms of an entire class of human disease.

Dr. Dixon received his B.S., B.M., and M.D. degrees from the University of Minnesota. Following three years of military service in World War II, he pursued his medical career in research and teaching at Harvard Medical School, Washington University Medical School, and the University of Pittsburgh School of Medicine, where he served as Professor and Chairman of the Pathology Department from 1951 to 1961.

Having received more than 20 major awards for his lifetime of scientific achievement, including election to the National Academy of Sciences, Dr. Dixon continues to serve on numerous scientific advisory committees for major organizations, including the National Kidney Foundation, the World Health Organization and the National Multiple Sclerosis Society.

**Kimishige Ishizaka, M.D., Ph.D.
President & Director Emeritus**

In 1989, Dr. Ishizaka joined LIAI as the Institute's first Scientific Director, and was elected to the additional office of President in 1991, serving in this dual role until his retirement in 1996. He is currently President Emeritus of LIAI.

Dr. Ishizaka and his wife Dr. Teruko Ishizaka received worldwide recognition in 1966 for their discovery of immunoglobulin E (IgE), an antibody contributing to allergic disease. Dr. Ishizaka accomplished this pioneering research while on the faculty of the Department of Microbiology at the University of Colorado Medical School, where he was first appointed Assistant Professor in 1962. He left Colorado for Johns Hopkins University in 1970, serving on the faculty of the School of Medicine and the Faculty of Arts and Science for nearly two decades.

Dr. Ishizaka received his M.D. and Ph.D. in immunology from the University of Tokyo. In the U.S., he undertook postdoctoral training in immunochemistry at the California Institute of Technology, and in immunology at The Johns Hopkins University School of Hygiene and Public Health.

Dr. Ishizaka has received numerous national and international awards for his scientific achievements, including his 1983 election to the National Academy of Sciences, the 1985 American College of Physicians Award for Achievement in Medical Science, and the 2000 Japan Prize from the Science and Technology Foundation of Japan. He also served as President of the American Association of Immunologists from 1984-85.

###